The 61st ASH Annual Meeting: Unwrapping the Best From Hematology's Christmas
2019 ASH News Daily Editor Dr. Ayesha Zia recaps the 61st ASH Annual Meeting and Exposition which took place early December in Orlando.
Single-cell Genomics Reveals the Cellular Landscape of Bone Marrow Stromal Cells
Drs. Chowdhury and Mead review a study that provides insights into cellular heterogeneity of mouse bone marrow stromal cells, which serve as a comprehensive resource for re
Dr. O'Dwyer and Dr. Huselton look at studies that observe the use of venetoclax regimens to treat acute myeloid leukemia in older patients or patients with comorbidities unable to use intensive induction chemotherapy.
Dr. Moll discusses three significant publications from 2019 on antiphospholipid syndrome.
Dr. Laura Michaelis ushers in 2020 introducing the 2019 "Year's Best" articles from our Contributing Editors while stressing challenges that remain in the translation of science into the public good and proposing some resolutions to help drive progress.
Drs. MacFarland and Teachey discuss genome-wide association studies that shed light on germline predisposition to childhood leukemia.
Dr. Zaidi and Dr. Osunkwo discuss efforts in 2019 to patch the gaps in our knowledge and understanding relating to both maternal and fetal management and outcomes of pregnancy in sickle cell disease.
Dr. Henden and Dr. Lane discuss work that sheds light on how mutations in acute myeloid leukemia contribute to leukemogenesis, providing rationale for precision-based therapies aimed at specific disease biology.
Dr. Jacobson covers studies that evaluate antibody-drug conjugates to change the standard of care for B- and T-cell non-Hodgkin lymphoma.
Dr. Linkins discusses direct oral anticoagulant thromboprophylaxis trials that compare risks and benefits for patients who are hospitalized or undergoing surgery.
Drs. Lomas and Ghobrial discuss trials from 2019 that assessed intervention in smoldering multiple myeloma (SMM) to determine whether the standard of practice to treat patients with high-risk SMM should change.
Drs. DeZern and Karantanos share exciting findings in the biologic understanding of TP53-mutated myelodysplastic syndromes which allow for future refinement to current therapeutic algorithms.
November-December 2019Volume 16, Issue 6
A new Compendium providing updated clinical information to "Ask the Hematologist" articles published in The Hematologist from 2010 to 2015 is now available.
AMERICAN SOCIETY OF HEMATOLOGY
2021 L Street NW, Suite 900, Washington, DC 20036
Phone 202-776-0544 | Fax 202-776-0545
by American Society of Hematology